Previous studies have demonstrated that HSPA5 expression is elevated in glioma specimens and silencing HSPA5 increases temozolomide chemosensitivity in malignant glioma cell lines [50], suggesting the potential roles of UPR in glioma chemoresistance. The gene discussed is HSPA5; the disease is central nervous system cancer.